Full year results 2024: portfolio makes good progress in challenging conditions
Commercial and financial developments during the year mean our portfolio is now a mix of companies at different stages of maturity. There was also strong technical progress across the portfolio. Despite the difficult funding environment, four companies raised money during the period and post the year end. We continued to strengthen management teams.
Read moreWatch: Frontier CEO Neil Crabb on full year results, portfolio progress and our fundraising
Neil takes Proactive’s Stephen Gunnion through the company’s annual results, the £3 million placing and subscription, as well as a separate offer to retail investors. Despite challenging financial markets, the company saw a modest gain in portfolio value and reduced losses, signalling resilience and growth potential.
Read moreWatch: The Vaccine Group CEO Dr Jeremy Salt on £400,000 Innovate UK grant for animal health
Dr Jeremy Salt talks about how The Vaccine Group will work with the Animal and Plant Health Agency to develop novel vaccines to combat cattle diseases. He also touches on future developments.
Read moreTVG collaboration with UK government agency awarded £400,000 by Innovate UK
The Vaccine Group and The Animal and Plant Health Agency will use the Smart grant money to develop cattle vaccines based on TVG’s innovative technology.
Read moreWatch: DeakinBio chief executive Dr Aled Roberts discuss the company’s innovative bio-materials
Dr Aled Roberts on the origins of the company’s low energy processes and advanced materials and how they will develop in the future.
Read moreDeakinBio raises £693,000 to scale up sustainable alternatives to ceramics
Portfolio company Deakin Bio-Hybrid Materials will use the proceeds to acclerate development and scale up of its low-energy processes and advanced bio-based materials.
Read moreWatch: TVG CEO Jeremy Salt on how Defra grant will help to tackle zoonotic pig disease
A project led by The Vaccine Group has been awarded more than £1 million by the UK government to develop a vaccine for Streptococcus suis. CEO Jeremy Salt explains why we need to tackle the bacterial disease and the potential for the company’s technology.
Read moreTVG led project to tackle zoonotic pig disease after winning £1m UK government grant
A project led by The Vaccine Group, University of Plymouth and University of Cambridge has been awarded more than £1 million by the UK government. The project aims to develop a vaccine to combat a widespread, harmful and zoonotic pig disease which is potentially fatal to humans.
Read moreNesta invests in Nandi Proteins
Portfolio company Nandi Proteins has raised £500,000 through a convertible loan. Investors include Nesta Impact Investments, the investment arm of UK social innovation agency Nesta, which has also committed to backing an equity funding round expected to complete later this year.
Read moreWatch Pulsiv Chief Product Officer Dr Tim Moore discuss the potential for the company’s groundbreaking technology
Pulsiv CPO Dr Tim Moore discusses the company’s 65W USB-C charger reference design and the technology’s wider potential, particularly as new EU regulations will make USB-C connectors mandatory across a wide range of devices.
Read morePulsiv launches world’s most efficient 65W USB-C charger reference design
Portfolio company Pulsiv has launched the world’s most efficient 65W USB-C reference design. The technology promises to expand and open up new markets for USB-C fast charging global standard.
Read moreWatch GraphEnergyTech CEO Thomas Baumeler discuss the potential of graphene electrodes
After raising £1 million through an investment round led by Aramco Ventures, GraphEnergyTech CEO outlines the company’s ambitions for its technology.
Read moreAramco Ventures backs GraphEnergyTech as part of £1 million fundraising
Aramco Ventures, the corporate venturing arm of Aramco, has invested in GraphEnergyTech as part of a £1 million funding round. Proceeds will be used to accelerate development and scalle up of the company’s advanced graphene electrodes.
Read moreCambridge Raman Imaging launches pre-Series A funding round
Cambridge Raman Imaging (CRI) has launched a pre-Series A funding round to accelerate growth of its innovative medical imaging technology. Learn more about the technology, why it is so exciting and what the company plans to do with the funding.
Read more